ZGNX News and Press, Zogenix Inc. From 05/08/19

Type A meeting with U.S. FDA expected by early June to discuss FINTEPLA® Dravet syndrome NDA expected by early June FINTEPLA Dravet syndrome MAA accepted for review by EMA Exclusive distribution agreement for FINTEPLA in Japan signed with Nippon Shinyaku EMERYVILL...

Zogenix (NASDAQ: ZGNX ) is scheduled to announce Q1 earnings results on Wednesday, May 8th, after market close. The consensus EPS Estimate is -$0.86 (+1.1% Y/Y) Over the last 2 years, zgnx has beaten EPS estimates 38% of the time and has beaten revenue estimates 38% of the time. Mo...

EMERYVILLE, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and CEO, and Michael P. Smith, Executive Vice President, CFO, Treasurer and Secretary,...

SAN DIEGO, CA / ACCESSWIRE / May 7, 2019 / The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in Zogenix, Inc. (NASDAQ: ZGNX) shares. Investors, who purchased shares of Zogenix, Inc. (NASDAQ: ZGNX), have certain options and should contact the Sharehol...

Putting the cart before the horse The typical course of drug R&D goes something like this: a druggable target is identified early discovery efforts are launched a lead drug candidate is selected preclinical studies are conducted an IND is filed PhI, PhII and PhIII trials ar...

EMERYVILLE, Calif., May 01, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three months ended March 31, 2019, after the market close, and will host a ...

Introduction and summary of investment thesis for Zogenix: I have been following Zogenix ( ZGNX ) for more than two years and had a >300% return since my initiation article (in 2017) after the company’s excellent data for its low dose fenfluramine formulation, ZX008 in treating...

NEW YORK, April 16, 2019 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Zogenix, Inc. ("Zogenix" or the "Company")(NASDAQ:ZGNX) of the June 11, 2019 deadline to seek the role of lead plaintiff in a federal securities class action t...

Brain and computer augmentation isn't all that far-fetched according to recent research, where electrical stimulation has improved memory in older adults and electrodes are enabling some high-tech prosthetics to transmit sensations to their users. Bryan Johnson and Elon Musk have both made...

SAN FRANCISCO , April 15, 2019 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Zogenix, Inc. (NASDAQ: ZGNX) to the firm's investigation of possible Federal securities law violations.  If you purchased or otherwise acquired Zogenix securities between January...